Previous 10 | Next 10 |
2023-08-20 03:50:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights for an anti-inflammatory drug to ONE Bio in a $1 billion deal. Shanghai Sangon Biotech raised $290 million in funding from private investors. Hangzhou Zhongmei Huadong Pharma in-licensed China-SE ...
2023-08-18 16:41:38 ET More on Arcutis Biotherapeutics Arcutis: Zoryve - A Challenging Launch With Progress Arcutis Biotherapeutics: High OpEx And Crowded Markets Cloud Prospects Arcutis inks licensing deal to launch psoriasis cream in Asia Arcutis down 20% o...
WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that John W. Smither, who served as Arcutis...
2023-08-10 09:14:59 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. ( ARQT ) Q2 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Arcutis: Zoryve - A Challenging Launch With Progress ...
Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...
2023-08-08 22:05:17 ET Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Conference Call August 08, 2023 04:30 PM ET Company Participants Eric McIntyre - Head-Investor Relations Frank Watanabe - President & Chief Executive Officer Ayisha Jeter - Interim-C...
2023-08-08 16:15:23 ET Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q2 GAAP EPS of -$1.16 beats by $0.08 . Revenue of $5.2M beats by $0.58M . Approximately $270 million in cash, cash equivalents, and marketable securities as of June 30, 2023. F...
Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of 2023, driven by nearly 40% demand growth as well as gross-to-net improvement Continued exp...
2023-08-02 13:00:00 ET Summary We've compiled a list of July investment picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. Featured here are the investmen...
2023-07-28 05:31:08 ET Summary Arcutis has launched Zoryve, a topical cream for the treatment of psoriasis, and is focused on transitioning to a commercial-stage company. The company has made progress with major pharmacy benefit managers and positioned Zoryve to be highly accessib...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U....
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...